DIKUL - logo
E-viri
Celotno besedilo
Recenzirano Odprti dostop
  • Dapagliflozin in Heart Fail...
    Solomon, Scott D.; McMurray, John J.V.; Claggett, Brian; de Boer, Rudolf A.; DeMets, David; Hernandez, Adrian F.; Inzucchi, Silvio E.; Kosiborod, Mikhail N.; Lam, Carolyn S.P.; Martinez, Felipe; Shah, Sanjiv J.; Desai, Akshay S.; Jhund, Pardeep S.; Belohlavek, Jan; Chiang, Chern-En; Borleffs, C. Jan Willem; Comin-Colet, Josep; Dobreanu, Dan; Drozdz, Jaroslaw; Fang, James C.; Alcocer-Gamba, Marco Antonio; Al Habeeb, Waleed; Han, Yaling; Cabrera Honorio, Jose Walter; Janssens, Stefan P.; Katova, Tzvetana; Kitakaze, Masafumi; Merkely, Béla; O’Meara, Eileen; Saraiva, Jose Francisco Kerr; Tereshchenko, Sergey N.; Thierer, Jorge; Vaduganathan, Muthiah; Vardeny, Orly; Verma, Subodh; Pham, Vinh Nguyen; Wilderäng, Ulrica; Zaozerska, Natalia; Bachus, Erasmus; Lindholm, Daniel; Petersson, Magnus; Langkilde, Anna Maria

    New England journal of medicine/˜The œNew England journal of medicine, 09/2022, Letnik: 387, Številka: 12
    Journal Article

    In a trial involving patients with heart failure and a mildly reduced or preserved ejection fraction, dapagliflozin reduced the risk of worsening heart failure or cardiovascular death.